Skip to content
Welcome to TransCelerate
TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.
Watch our About Us video
Q1 2024 Pulse on Progress Available
The Q1 2024 Pulse on Progress newsletter highlights all of the recently launched solutions available to the public and our upcoming events. Read on to see how TransCelerate is helping to improve the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies.
Read about our new solutions
Inspiring Inclusion: The Power of Pivotal Moments
TransCelerate CEO Janice Chang joined Rob Goodwin (Pfizer), Ester Krofah (Milken Institute Health), Joni Rutter (National Center for Advancing Translational Sciences, National Institutes of Health), and Janet Woodcock (former Principal Deputy Commissioner, Food & Drug Administration) for a special panel on "Inspiring Inclusion: The Power of Pivotal Moments" in honor of International Women's Day.
Watch the roundtable
2023 Annual Achievements Report Available
TransCelerate's 2023 Annual Achievements Report is now available. Read on for an in-depth look at our impact within biopharma R&D, our publicly available solutions and resources, and how we are working to converge clinical research with clinical care.
Read the Annual Report
Gilead Sciences Joins TransCelerate
Gilead Sciences, Inc. (Gilead), a leading biopharmaceutical company that has achieved breakthroughs in medicine for more than three decades, has joined TransCelerate as its newest member.
Read the Press Release
TransCelerate & ACRO Release Key Risk Management Considerations in Clinical Practice (ICH E6 (R3))
TransCelerate and ACRO co-created an infographic highlighting key changes to the risk management elements within Good Clinical Practice. It aims to allow the R&D industry to easily identify the impact to their process and how to react for efficient ICH E6 (R3) implementation.
View the Infographic
Merz Aesthetics Joins TransCelerate
Merz Aesthetics, a leader in aesthetics with an award-winning line of injectables, devices, and skin care products, has joined TransCelerate BioPharma as an Associate Member.
TransCelerate Members
GCP Mutual Recognition
The TransCelerate Site Qualification and Training (SQT) Initiative has developed a Mutual Recognition (MR) Program for ICH E6 Good Clinical Practice (GCP) Training, targeted to investigator site personnel. Our GCP Mutual Recognition program was created to reduce redundant training and hours spent by investigators who need to complete the same training if they work with multiple sponsors.
More Info
Translated Solutions
TransCelerate Member Companies have translated select solutions for potential use within the broader global community. Current translations include solutions concerning Common Protocol Template, Site Qualification & Training, Quality Management Systems and Patient Experience.
Read More

Upcoming Events

Virtual • May 16

Webinar: Pharmacovigilance Agreement Solutions You Didn’t Realize You Needed

Join us for an overview of TransCelerate’s Pharmacovigilance Agreements Optimization (PVAO) Initiative, which includes a suite of solutions designed to help organizations enhance their PVA process. These solutions can help organizations improve their processes and potentially achieve more efficient negotiations with business partners globally. ​ The webinar will include: ​ Panelists: Ideal Attendees: TransCelerate webinars may be recorded in whole or…

Read more

More Events

Learn More About TransCelerate’s Mission